Conversely, S1P has also been shown to be an antagonist of IPF by strengthening the integrity of the endothelial barrier via S1P receptor 1 (S1PR1)/Rac pathways and constricting pulmonary inflammation [13]. Here, AKT1 is linked to idiopathic pulmonary fibrosis.